What Is a Low CTE Filler? Why Fused and Spherical Silica Are Preferred

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: 2500 Mesh Silica: Particle Size, Specifications and Common Applications
  • Keywords: thermal conductive filler
  • Published: 2026-11-20 08:53:54
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
The size of the particles greatly affects the interaction with epithelial cells, cellular absorption, and therefore their effectiveness [ 1, 10, 12 ]. Furthermore, the size also influences the leakage of the API [ 12 ]. It has been proven in vitro that epithelial permeability can be increased by decreasing the size [ 1, 12, 13, 24 ]. Zhang et al. also observed that the cellular uptake of MSNs occurred in a time-, concentration-, and size-dependent manner based on in vitro studies performed on Caco-2 cell lines (20 nm, 60 nm, 90 nm) [ 24 ]. Nevertheless, more complex findings were gained in vivo. Wang et al. compared differently sized nanoparticles in various elements (100 nm, 250 nm, 480 nm) [ 12 ]. Similarly, Lamson et al. compared MSNs with different sizes to observe the influence of the particle size on bioavailability (20-1200 nm) [ 13 ]. Larger particles (normally around 500 nm) show slower release of the API and can form a strong interaction with the cell membrane [ 12 ], but cellular uptake is limited owing to their large size [ 1, 12 ]. Smaller particles (below 100 nm) show weaker interaction with the cell membrane but exert superb cellular uptake owing to their small size [ 12 ]. On the other hand, the smaller particles can slowly diffuse through the mucin layer covering the surface of the intestinal mucosa, become trapped in it, and aggregate, further worsening the absorption [ 1, 12, 13 ]. Furthermore, the decreasing particle size leads to increased release rate, owing to the larger specific surface area and faster degradation of the particles [ 1, 12 ], which can lead to early leakage of the molecules, worsening their absorption [ 1, 12 ]. As the diameter increases, the rate of degradation and drug release kinetics decreases, so larger particles have a longer half-life [ 12 ].

Precipitated Silica Manufacturer: Production Process and Supplier Selection Guide

Silica Matting Agent: How It Works, Key Specs and How to Choose the Right Grade
Talc Powder vs Silica: Differences and Which Filler to Choose
Not certain where to start with diatomaceous earth? The amount of conflicting details about DE can be overwhelming. Find everything you have to be confident in taking your first steps with DE below.
Amorphous vs Crystalline Silica: Structure, Safety and Uses Compared
Mesoporous silica nanoparticles have poor powder rheology and poor flow properties, due to their low bulk density, small particle size, and high hygroscopicity, which make further processing and formulation, especially with direct compression, difficult [ 104 ]. This issue can be eliminated by granulating the carriers. Flowability and compactibility can also be boosted by granulation [ 86, 104 ]. During granulation, the desired degree of dispersity is attained by agglomeration of the particles, thereby creating a best possible flow characteristic. However, it is true that during granulation, the specific surface area and the pore volume of the carrier may decrease, also decreasing its adsorption capacity, which is a disadvantage from the facet of the API absorption [ 104, 105 ]. However, since this reduction is mostly negligible compared to the total specific surface area, a substantial improvement in its flow properties can considerably improve the overall performance [ 104, 105 ]. The critical parameters for the process are the following: the quantity of granulating liquid, the liquid addition rate, the mixing speed, the process time, and the temperature. Of course, the applied binder also plays an essential part in the process [ 105 ]. These parameters affect the granule size, specific surface area, bulk density, flow properties (Hausner-factor, Carr-index), crushing strength, compressibility, and compactibility [ 105 ].
Quartz Sand Supplier: How to Choose by Purity, Grain Size and Logistics
Magnetic particles were synthesized with an iron-containing coating. The model drugs were safranin O and hydrocortisone. The particles were functionalized with a bulky azo derivative to act as a gatekeeper and stop early leakage of the drug. In vitro release models have demonstrated that most of the drug is released only in the colon, as desired. This is owing to the reductive environment in the colon (the presence of the azoreductase enzyme), where the enzymatic degradation of the azo bond resulted in controlled release. In addition, in vivo pharmacokinetic studies were conducted in a rat model of induced colitis to test the effect of the magnetic field during therapy. The findings boosted when the rats wore a magnetic belt, which extended the retention time of the particles in the desired areas [ 75 ]. Zhang et al. presented a study in which magnetic silica nanoparticles (filled with sulforaphane) were developed for the treatment of myocardial infarction [ 38 ]. In mouse models, effective accumulation was observed in the infarcted zone after the application of an external magnetic field [ 33, 75 ]. These results show the potential of using magnetic particles with magnetic field guidance [ 33 ]. Radhakrishnan et al. developed a drug delivery system (DDS) loaded with carboplatin for targeted lung cancer therapy [ 63 ]. The DDS was core-shell mesoporous silica functionalized with folic acid. Initially, the drug loading capability of the functionalized carrier was more than twice as high per surface unit compared to the non-functionalized carrier due to the anchored -NH 2 groups. The drug release was sustained but limited (up to 36%) in the case of the functionalized particle, similarly to previous cases. This is most likely owing to the stronger interactions between the amine groups and the carboplatin. The amino-functionalized particles were further functionalized with folic acid to increase cellular uptake of the particles, demonstrating the potential of folic acid-targeted therapy [ 63, 65, 76 ]. Cancer cells typically overexpress folate receptors, resulting in folate-mediated internalization that preferentially targets these cells [ 63, 76 ]. This was demonstrated in a drug-mediated cytotoxicity analysis where amino- and folate-functionalized particles were evaluated and compared. Much greater cytotoxicity was observed in cells overexpressing folate receptors [ 63 ]. Similar research was carried out by Shirani et al., where folic acid functionalized MSNs were loaded with gemcitabine as a model drug, to investigate its potential in cancer treatment, while actively targeting cancer cells [ 70 ]. Outcomes have shown that higher cellular uptake (HeLa and K562 cells) was observed in the case of the functionalized particles, compared with the non-functionalized carriers [ 70 ]. Jafarpour et al. demonstrated the importance of functionalizing the carriers to accomplish targeted therapy utilizing methotrexate as a model drug [ 76 ]. The particles were grafted with a copolymer to act as a pH-responsive gatekeeper and folic acid to actively target cancer cells [ 76 ]. Ortiz et al. similarly designed a pH-responsive DDS, loaded with the anticancer drug doxorubicin [ 11 ]. The particles were functionalized with transferrin through a pH-sensitive linker as a gatekeeper, controlling the release kinetics and preventing early leakage of the drug [ 11 ]. An interesting breast cancer therapy was published by Mal et al. using doxorubicin as API and mesoporous silica as a carrier [ 65 ]. The amine-functionalized MSNs were PEGylated and then conjugated with folic acid or hyaluronic acid. It was also published that coating the nanoparticles with polydopamine (PDA) and polyethylene glycol (PEG) brings about prolonged doxorubicin release from MSNs [ 77 ]. These conjugates enabled ligand-mediated targeted drug delivery [ 65 ]. Researchers have developed a successful DDS that targets cancer cells, thus staying away from the side effects associated with doxorubicin in conventional cancer therapy. This is important because in vitro cytotoxicity studies have shown that the free drug has higher cytotoxicity than the nanocarriers [ 65 ]. Shahbaz et al. developed a redox-responsive silica nanocarrier loaded with paclitaxel to target breast cancer cells [ 67 ]. The amine-functionalized silica core was coated with disulfide-functionalized non-porous silica shell. Then the core-shell carriers were further coated with polyethylene glycol via disulfide linkages. In vitro drug release assay verified the correlation between the redox potential of the environment and the release kinetics. This is an important finding, as it has been revealed that cancer cells possess a higher redox ability than healthy cells. This provides controlled paclitaxel release for targeted therapy. According to cell uptake and cell viability assays, this DDS is noticeably more effective than free paclitaxel, making this nanocarrier an exciting prospect [ 67 ]. These illustrations highlight the importance of surface functionalization and employing stimuli-responsive gatekeepers to attain productive targeted therapy.

Silica as a Thickening Agent: How It Works in Liquids, Resins and Gels

What is silica (SiO₂)?

silica manufacturer India

What is the difference between fumed silica and precipitated silica?

Nouryon Levasil

What drives silica raw material prices?

silica slurry One of the biggest challenges of tableting greatly potent APIs (antibiotics, hormones, cytostatic molecules) is to attain content uniformity [ 95, 96 ]. Since these molecules are used in small doses, it is demanding to attain a homogeneous powder mixture during mixing and to make sure this homogeneity until the end of tableting. Also, it is a hurdle to develop a reproducible method that ensures content uniformity for each production batch, since the specified dose must be made sure between batches, not just within one batch [ 95, 96 ]. A reliable alternative method is to use mesoporous silica as a carrier system rather than simple powder mixing, thus preventing the segregation and aggregation of the low-dose API during mixing and compression. In this case, the preloaded mesoporous carrier and the necessary excipients are mixed, and then the powder mixture can be compressed directly or after granulation. The drug loading can be controlled by the concentration of the drug solution used to fill the carrier systems, which affects the amount of the drug content in the concluding medicine [ 95, 96 ]. Based on this, nearly unlimitedly low doses can be formulated into tablets, even in a concentration of 0.01%, just by properly preparing the solution [ 96 ]. The technique is well-controllable and dependable, since each tablet has the same drug content and the desired content uniformity. Furthermore, the method can be used in both batch-based and continuous production [ 96 ]. This may be a promising finding because there is evidence that it is challenging to move from batch-based to continuous manufacturing while maintaining the desired drug content and content uniformity [ 94 ]. But it should be noted that in this study, no nanocarrier system was used [ 94 ], so utilizing MSN formulations could make an enormous improvement in developing continuous tablet manufacturing [ 96 ]. A study shown that MSN carriers can also be used in orodispersible films to enhance the dissolution of poorly water-soluble drugs [ 100 ]. Based on in vitro drug release studies, more than 90% of prednisolone was released within 2 min when the loaded MSN was incorporated into the formulation. This means a much faster, immediate release in comparison with formulations containing the free form of the drug. In addition, precise dosing can be accomplished utilizing nanocarriers for personalized medication; furthermore, enabling the production of low-dose preparations without content uniformity problems [ 100 ].

Cite this article: Silica Raw Materials News. "Silica Glidant for Tablets: How It Improves Powder Flow and Typical Dosages ." Published 2026-11-20 08:53:54. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.